Related Experiment Video
Updated: Apr 30, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible
Fiona M Fennessy1, Rana R McKay2, Clair J Beard3
1Department of Radiology, Brigham and Women's Hospital, Boston, MA ; Department of Radiology, Dana-Farber Cancer Institute, Boston, MA.
Abstract:
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluates the tissue microvasculature and may have a role in assessing and predicting therapeutic response in prostate cancer (PCa). In this review, we review principles of DCE-MRI and present the potential quantitative information that can be obtained. We discuss how it may be used as a biomarker for treatment with antiangiogenic and antivascular agents and potentially identify patients with PCa who may benefit from this form of therapy. Likewise, DCE-MRI may play a role in assessing response to combined androgen deprivation therapy and radiation therapy and theoretically could be a prognostic biomarker in evaluating second-generation hormone therapies. We also address the challenges of using DCE-MRI in PCa clinical trials and discuss the difficulties with standardization of this methodology to allow for biomarker validation, with particular reference to PCa.
More Related Videos
Related Concept Videos
Magnetic Resonance Imaging
Imaging Studies IV: Magnetic Resonance Imaging
Imaging Studies I: CT and MRI
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...
Imaging Studies for Cardiovascular System IV: CMRI

